Hafnarfjodur – Actavis Group CEO Claudio Albrecht announced at the beginning of February that the company may go public within the next 2-3 years, although it isn’t clear whether the generics manufacturer would conduct an IPO, sell the business, or hook up with another company. As a privately-held company, Actavis doesn’t publish full financial reports, but Albrecht disclosed that the firm’s financial results last year were the best in the company’s history. Revenues reached a1.8bn, and earnings before interest, tax, depreciation and amortisation (EBITDA) exceeded EUR300m. In order to continue on its path to prosperity, Actavis is looking for acquisitions ranging from EUR400m-EUR500m. According to the company, targets for acquisition would preferably be situated in Poland, Russia, Turkey or southern Europe.